Lineage Cell Therapeutics (LCTX) Non-Current Deffered Revenue (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Non-Current Deffered Revenue of $13.0 million for Q1 2026, down 4.5% year-over-year from $13.6 million in Q1 2025, and up 5.03% quarter-over-quarter from $12.4 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Non-Current Deffered Revenue history runs 16 years deep, the most recent figure standing at $13.0 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 4.5% year-over-year to $13.0 million; the TTM figure through Mar 2026 stood at $13.0 million (down 4.5% YoY), while the FY2025 annual figure was $12.4 million, down 14.25% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $13.0 million, up from $12.4 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $30.8 million in Q1 2022, with the low at $12.4 million in Q4 2025.
- The 5-year median for Non-Current Deffered Revenue is $18.5 million (2024), against an average of $19.3 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Deffered Revenue tumbled 32.58% in 2023, then retreated 4.5% in 2026.
- Lineage Cell Therapeutics' Non-Current Deffered Revenue stood at $27.7 million in 2022, then tumbled by 32.58% to $18.7 million in 2023, then decreased by 22.79% to $14.4 million in 2024, then slipped by 14.25% to $12.4 million in 2025, then gained by 5.03% to $13.0 million in 2026.
- Business Quant data shows LCTX's Non-Current Deffered Revenue at $13.0 million in Q1 2026, $12.4 million in Q4 2025, and $12.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 12.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.34 Mn |
| Mar 31, 2026 | 13.00 Mn |
| Dec 31, 2025 | 12.38 Mn |
| Sep 30, 2025 | 12.46 Mn |
| Jun 30, 2025 | 12.75 Mn |
| Mar 31, 2025 | 13.61 Mn |
| Dec 31, 2024 | 14.43 Mn |
| Sep 30, 2024 | 16.05 Mn |
| Jun 30, 2024 | 18.54 Mn |
| Mar 31, 2024 | 18.18 Mn |
| Dec 31, 2023 | 18.69 Mn |
| Sep 30, 2023 | 21.20 Mn |
| Jun 30, 2023 | 21.69 Mn |
| Mar 31, 2023 | 24.02 Mn |
| Dec 31, 2022 | 27.73 Mn |
| Sep 30, 2022 | 26.54 Mn |
| Jun 30, 2022 | 25.77 Mn |
| Mar 31, 2022 | 30.82 Mn |
| Dec 31, 2021 | 32.45 Mn |
| Dec 31, 2019 | 200,000.00 |